查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566765

免疫血液学市场：按产品、应用和最终用户：2024-2033 年全球机会分析和产业预测

Immunohematology Market By Product (Analyzers and Systems, Reagents) , By Application (Blood-related Diseases, HIV, Others) By End User (Hospitals, Diagnostic Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 233 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球免疫血液学市场价值为19亿美元，预计2024年至2033年复合年增长率为4.6%，到2033年将达30亿美元。

免疫血液学，也称为血库或输血医学，是实验医学的一个专门领域，重点研究与输血相关的血型和抗体。辨识并表征红血球表面存在的血型抗原以及血浆中存在的相应抗体。免疫血液学的主要目标是透过匹配捐赠者和受体血型并防止副作用来确保安全和相容的输血。该部门在输血治疗、器官移植和各种血液疾病的治疗中发挥重要作用。

全球免疫血液学市场的成长是由慢性病盛行率上升和外科手术数量迅速增加所推动的，这导致了对安全输血实践至关重要的准确血型和交叉配血，从而显着增加了对血液的需求。此外，随着人口老化，贫血、白血病等发生率不断增加，进一步增加了对免疫血液学产品的需求。此外，对血液安全和捐赠者相容性的认识不断提高和严格的法规也有助于免疫血液学市场的扩大成长。

然而，先进的免疫血液学检测设备和试剂的高成本可能会限制其采用，特别是在医疗保健预算有限的发展中地区。同时，采用自动化数位血液检测平台具有提高诊断准确性和效率的巨大潜力，并满足对快速可靠的血型和交叉配血日益增长的需求。例如，2023年5月，Bio-Rad Laboratories, Inc.宣布推出IH-500TM NEXT系统，这是一款全自动ID卡系统。 IH-500 NEXT 系统与 Bio-Rad 的 ID 卡一起使用，并描述了用于常规测试（分型和筛检）和专业测试（包括单抗原分型和新生儿筛检）的广泛产品组合。

细分概述

全球免疫血液学市场分为产品、应用、最终用户和地区。根据产品，市场分为分析仪器和系统以及试剂。依用途分为血液相关疾病、爱滋病毒等。依最终用户划分，可分为医院、诊断实验室等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按产品划分，试剂细分市场在 2023 年占据最高份额。

从应用来看，2023年血液相关疾病领域占最大份额。

按最终用户划分，2023 年医院领域占最大份额。

按地区划分，北美在 2023 年主导全球免疫血液学市场。

竞争场景

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章免疫血液学市场：副产品

  • 市场概况
  • 分析仪和系统
  • 试剂

第五章免疫血液学市场：依应用分类

  • 市场概况
  • 血液相关疾病
  • 爱滋病毒感染疾病
  • 其他的

第六章免疫血液学市场：依最终用户分类

  • 市场概况
  • 医院
  • 诊断实验室
  • 其他的

第七章免疫血液学市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国免疫血液学市场
    • 加拿大免疫血液学市场
    • 墨西哥免疫血液学市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国免疫血液学市场
    • 法国免疫血液学市场
    • 英国免疫血液学市场
    • 义大利免疫血液学市场
    • 西班牙免疫血液学市场
    • 其他欧洲免疫血液学市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本免疫血液学市场
    • 中国免疫血液学市场
    • 印度免疫血液学市场
    • 澳洲免疫血液学市场
    • 韩国免疫血液学市场
    • 其他亚太免疫血液学市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西免疫血液学市场
    • 沙乌地阿拉伯免疫血液学市场
    • 南非免疫血液学市场
    • 其他拉丁美洲、中东和非洲国家的免疫血液学市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Bio-Rad Laboratories, Inc
  • Werfen
  • Grifols, SA
  • Danaher Corporation
  • Siemens
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Cardinal Health
简介目录
Product Code: A01796

The global immunohematology market was valued at $1.9 billion in 2023, and is projected to reach $3.0 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

Immunohematology, also known as blood banking or transfusion medicine, is a specialized branch of laboratory medicine that focuses on the study of blood groups and antibodies associated with blood transfusion. It involves the identification and characterization of blood group antigens on the surface of red blood cells and the corresponding antibodies present in plasma. The main goal of immunohematology is to ensure safe and compatible blood transfusions by matching the blood type of the donor with that of the recipient to prevent adverse reactions. This field plays a crucial role in transfusion therapy, organ transplantation, and managing various hematologic disorders.

The growth of the global immunohematology market is driven by rise in the prevalence of chronic diseases and surge in the number of surgical procedures, which have significantly boosted the need for accurate blood typing and cross-matching, which are crucial for safe transfusion practices. In addition, aging population has led to a higher incidence of conditions such as anemia and leukemia, further escalating the demand for immunohematology products. Moreover, rise in awareness and stringent regulations regarding blood safety and donor compatibility are contributing to the expansion of immunohematology market growth.

However, high cost associated with advanced immunohematology instruments and reagents, which can limit their adoption, especially in developing regions with limited healthcare budgets. On the other hand, adoption of automated and digital blood testing platforms offers significant potential for improving diagnostic accuracy and efficiency, catering to the growing demand for rapid and reliable blood typing and cross-matching. For instance, in May 2023, Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID-Cards. The IH-500 NEXT System is used with Bio-Rad's ID-Cards, offering a broad portfolio for both routine testing (type and screen) and specialized testing, including single antigen determination and newborn screening.

Segmentation Overview

The global immunohematology market is segmented into product, application, end user, and region. Depending on the product, the market is categorized into analyzers & systems and reagents. By application, it is classified into blood-related diseases, HIV, and others. According to end user, the market is divided into hospitals, diagnostic Laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the reagents segment held the highest share in the market in 2023.

Depending on the application, the blood-related diseases segment accounted for the maximum market share in 2023.

According to end user, the hospitals segment was the largest shareholder in 2023.

Region wise, North America dominated the global immunohematology market in 2023.

Competitive Scenario

The major players operating in the immunohematology market include Bio-Rad Laboratories, Inc, Werfen, Grifols, S.A., Danaher Corporation, Siemens, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche Ltd, and Cardinal Health. These players have adopted several tactics such as product advancement & diversification, mergers & acquisitions, partnerships, collaborations, and advertising to strengthen their position in the competitive environment.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Analyzers and Systems
  • Reagents

By Application

  • Blood-related Diseases
  • HIV
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bio-Rad Laboratories, Inc
    • Werfen
    • Grifols, S.A.
    • Danaher Corporation
    • Siemens
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd
    • Cardinal Health

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: IMMUNOHEMATOLOGY MARKET, BY PRODUCT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product
  • 4.2. Analyzers And Systems
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Reagents
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: IMMUNOHEMATOLOGY MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Blood-related Diseases
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. HIV
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: IMMUNOHEMATOLOGY MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: IMMUNOHEMATOLOGY MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Product
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Immunohematology Market
      • 7.2.6.1. Market Size and Forecast, By Product
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Immunohematology Market
      • 7.2.7.1. Market Size and Forecast, By Product
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Immunohematology Market
      • 7.2.8.1. Market Size and Forecast, By Product
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Product
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Immunohematology Market
      • 7.3.6.1. Market Size and Forecast, By Product
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Immunohematology Market
      • 7.3.7.1. Market Size and Forecast, By Product
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Immunohematology Market
      • 7.3.8.1. Market Size and Forecast, By Product
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Immunohematology Market
      • 7.3.9.1. Market Size and Forecast, By Product
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Immunohematology Market
      • 7.3.10.1. Market Size and Forecast, By Product
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Immunohematology Market
      • 7.3.11.1. Market Size and Forecast, By Product
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Product
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Immunohematology Market
      • 7.4.6.1. Market Size and Forecast, By Product
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Immunohematology Market
      • 7.4.7.1. Market Size and Forecast, By Product
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Immunohematology Market
      • 7.4.8.1. Market Size and Forecast, By Product
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Immunohematology Market
      • 7.4.9.1. Market Size and Forecast, By Product
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Immunohematology Market
      • 7.4.10.1. Market Size and Forecast, By Product
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Immunohematology Market
      • 7.4.11.1. Market Size and Forecast, By Product
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Product
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Immunohematology Market
      • 7.5.6.1. Market Size and Forecast, By Product
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Immunohematology Market
      • 7.5.7.1. Market Size and Forecast, By Product
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Immunohematology Market
      • 7.5.8.1. Market Size and Forecast, By Product
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Immunohematology Market
      • 7.5.9.1. Market Size and Forecast, By Product
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Bio-Rad Laboratories, Inc
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Werfen
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Grifols, S.A.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Danaher Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Siemens
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Thermo Fisher Scientific Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Abbott Laboratories
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Merck KGaA
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. F. Hoffmann-La Roche Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Cardinal Health
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments